Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia

European Respiratory Journal

Volumn 38, Issue 1, 2011, Pages 36-41

  Singanayagam, A ^a   Chalmers, J D ^a   Akram, A R ^a   Hill, A T ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; Community acquired pneumonia; Inhaled corticosteroids; Outcome

Indexed keywords

BECLOMETASONE; BUDESONIDE; C REACTIVE PROTEIN; CICLESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; SALMETEROL;

AGED; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PNEUMONIA SEVERITY INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPIROMETRY; TREATMENT OUTCOME; UNITED KINGDOM;

ADRENAL CORTEX HORMONES; AGED; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; INHALATION EXPOSURE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMONIA; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 79960201163     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00077010     Document Type: Article

References (29)

1. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789. (Pubitemid 46294610)
2. Kardos P, Wencker M, Glaab, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations n severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144-149. (Pubitemid 46115085)
3. Wedzicha JA, Calverley PM, Seenmungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19-26.
4. Rello J, Rodriguez A, Torres A, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006; 27: 1210-1216. (Pubitemid 44914306)
5. Restrepo MI, Mortensen EM, Pugh JA, et al. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006; 28: 346-351. (Pubitemid 44914234)
6. Holguin F, Folch E, Redd SC, et al. Comorbidity and mortality in COPD-related hospitalisations in the United States. 1979-2001. Chest 2005; 128: 2005-2011.
7. Torres A, Menendez R. Mortality in COPD patients with community-acquired pneumonia: who is the third partner? Eur Respir J 2006; 28: 262-263.
8. Torres A, Dorca J, Zalacaín R, et al. Community-acquired pneumonia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154: 1456-1461. (Pubitemid 26391197)
9. Ruiz De Ona JM, Gomez Fernandez M, Celdran J, et al. Pneumonia in the patient with chronic obstructive pulmonary disease. Levels of severity and risk classification. Arch Bronchoneumol 2003; 39: 101-105.
10. Crim C, Calverley PMA, Anderson JA, et al. Pneumonia risk in COPD patient receiving inhaled corticosteroids alone or in combination: TORCH study result. Eur Respir J 2009; 34: 641-647.
11. Singanayagam A, Chalmers JD, Hill AT. Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association. QJM 2010; 103: 379-385.
12. Singanayagam A, Chalmers JD, Hill AT. Admission hypoglycaemia is associated with adverse outcome in community-acquired pneumonia. Eur Respir J 2009; 34: 932-939.
13. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD www.goldcopd.com/ Guidelineitem.asp?l1=2&l2=1&intId=989 Date last accessed:March 23, 2010. Date last updated: December 2010.
14. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-382. (Pubitemid 36560938)
15. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250. (Pubitemid 27044625)
16. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64: Suppl. 3, iii1-iii55.
17. Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with community acquired pneumonia. Arch Intern Med 2002; 162: 1278-1284. (Pubitemid 34595034)
18. Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 760-765. (Pubitemid 39298991)
19. Llewellyn-Jones CG, Harris TA, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996; 153: 616-621. (Pubitemid 26051337)
20. van Overveld FJ, Demkow UA, Górecka D, et al. Inhibitory capacity of different steroids on neutrophil migration across a bilayer of endothelial and bronchial epithelial cells. Eur J Pharmacol 2003; 477: 261-267. (Pubitemid 38366399)
21. Malo de Molina R, Mortensen EM, Restrepo MI, et al. Inhaled corticosteroid use is associated with lower mortality for subjects with chronic obstructive pulmonary disease and hospitalized with pneumonia. Eur Respir J 2010; 36: 751-757.
22. Salluh JI, Povoa P, Soares M, et al. The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit Care 2008; 12: R76.
23. Gorman SK, Slavik RS, Marin J. Corticosteroid treatment of severe community-acquired pneumonia. Ann Pharmacother 2007; 41: 1233-1237. (Pubitemid 47122561)
24. Van De Garde EM, Oosterheert JJ, Bonten M, et al. International classification of diseases codes show modest sensitivity for detecting community-acquired pneumonia. J Clin Epidemiol 2007; 60: 834-838. (Pubitemid 46990803)
25. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic-obstructive pulmonary disease. A systematic review and meta-analysis. JAMA 2008; 300: 2407-2416.
26. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic-obstructive pulmonary disease. A meta-anaysis. Arch Intern Med 2009; 169: 219-229.
27. Woodhead M. Inhaled corticosteroids cause pneumonia... or do they? Am J Respir Crit Care Med 2007; 176: 111-112.
28. Rees PJ. Inhaled corticosteroids do not reduce mortality but increase pneumonia in COPD. Evid Based Med 2009; 14: 74.
29. Sin DD, Tashkin D, Zhang X, et al. Budesonide and risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712-719.